Incoming Senate Finance Committee member Ron Wyden (D-Ore.) is likely to play a central role in the push for legislation to give HHS greater leverage over drug pricing under Medicare
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.
